RU2005129333A - 4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения - Google Patents
4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения Download PDFInfo
- Publication number
- RU2005129333A RU2005129333A RU2005129333/04A RU2005129333A RU2005129333A RU 2005129333 A RU2005129333 A RU 2005129333A RU 2005129333/04 A RU2005129333/04 A RU 2005129333/04A RU 2005129333 A RU2005129333 A RU 2005129333A RU 2005129333 A RU2005129333 A RU 2005129333A
- Authority
- RU
- Russia
- Prior art keywords
- methoxyphenyl
- dichloro
- amino
- methoxy
- ethoxy
- Prior art date
Links
- 230000000302 ischemic effect Effects 0.000 title claims 12
- -1 2,4-Dichloro-5-methoxyphenyl Chemical group 0.000 title claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims 2
- 238000000034 method Methods 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000008728 vascular permeability Effects 0.000 claims 3
- NPTUGALLOCBPCM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl NPTUGALLOCBPCM-UHFFFAOYSA-N 0.000 claims 2
- JQGPWNQWNMMMAS-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl JQGPWNQWNMMMAS-UHFFFAOYSA-N 0.000 claims 2
- OSJKQGUEJYZHQM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl OSJKQGUEJYZHQM-UHFFFAOYSA-N 0.000 claims 2
- FCIILWHQWNLPJU-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl FCIILWHQWNLPJU-UHFFFAOYSA-N 0.000 claims 2
- QXWCRBMAGJJKTO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl QXWCRBMAGJJKTO-UHFFFAOYSA-N 0.000 claims 2
- HOHWAQXKWAAULM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCC1COC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC HOHWAQXKWAAULM-UHFFFAOYSA-N 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000324 neuroprotective effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- PCSXTJQETYJEOI-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCN3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl PCSXTJQETYJEOI-UHFFFAOYSA-N 0.000 claims 1
- FEPWXPAVJHFWGS-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCN(CC)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl FEPWXPAVJHFWGS-UHFFFAOYSA-N 0.000 claims 1
- SNJXHAGNHXWXDO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl SNJXHAGNHXWXDO-UHFFFAOYSA-N 0.000 claims 1
- TXAYKQMEBQBGLR-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl TXAYKQMEBQBGLR-UHFFFAOYSA-N 0.000 claims 1
- UNVLTPQRCHRNDB-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UNVLTPQRCHRNDB-UHFFFAOYSA-N 0.000 claims 1
- SUGCHLACYQMXHH-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-propylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1CN(CCC)CCN1CCCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC SUGCHLACYQMXHH-UHFFFAOYSA-N 0.000 claims 1
- JYNBIMGGLJKDLR-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-ethylpiperazin-1-yl)ethoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCN1CCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC JYNBIMGGLJKDLR-UHFFFAOYSA-N 0.000 claims 1
- BIEFBSIFAKMKOT-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCN1CCCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC BIEFBSIFAKMKOT-UHFFFAOYSA-N 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims 1
- 206010028923 Neonatal asphyxia Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004776 neurological deficiency Effects 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000005809 status epilepticus Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44931603P | 2003-02-21 | 2003-02-21 | |
| US60/449,316 | 2003-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005129333A true RU2005129333A (ru) | 2006-01-27 |
Family
ID=32927510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005129333/04A RU2005129333A (ru) | 2003-02-21 | 2004-02-19 | 4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040229880A1 (https=) |
| EP (1) | EP1594502A1 (https=) |
| JP (1) | JP2006522023A (https=) |
| KR (1) | KR20050102133A (https=) |
| CN (1) | CN1750824A (https=) |
| AR (1) | AR043253A1 (https=) |
| AU (1) | AU2004216235A1 (https=) |
| BR (1) | BRPI0407441A (https=) |
| CA (1) | CA2516418A1 (https=) |
| CO (1) | CO5640114A2 (https=) |
| CR (1) | CR7931A (https=) |
| EC (1) | ECSP055972A (https=) |
| MX (1) | MXPA05008706A (https=) |
| NO (1) | NO20054070L (https=) |
| RU (1) | RU2005129333A (https=) |
| TW (1) | TW200423938A (https=) |
| UA (1) | UA80472C2 (https=) |
| WO (1) | WO2004075898A1 (https=) |
| ZA (1) | ZA200506621B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120749B2 (en) | 2010-07-30 | 2015-09-01 | Oncotherapy Science, Inc. | Quinoline derivatives and MELK inhibitors containing the same |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1680119A1 (en) | 2003-11-06 | 2006-07-19 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| JP2008517924A (ja) * | 2004-10-22 | 2008-05-29 | ワイス | 虚血傷害を処置するための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−７−エチニル−３−キノリンカルボニトリル |
| EP1902029B2 (en) * | 2005-07-01 | 2022-02-16 | Wyeth LLC | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same |
| CN103772392A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| WO2015123758A1 (en) * | 2014-02-20 | 2015-08-27 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| US20160256457A1 (en) * | 2014-06-10 | 2016-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating or preventing acute vascular leak |
| EP3227276B1 (en) | 2014-12-02 | 2021-09-01 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| WO2017029584A1 (en) * | 2015-08-19 | 2017-02-23 | Sun Pharmaceutical Industries Limited | Amorphous form of bosutinib |
| BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| CN107814769B (zh) * | 2016-09-14 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种博舒替尼的纯化方法 |
| AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| CN111646940B (zh) * | 2019-03-04 | 2024-01-30 | 鲁南制药集团股份有限公司 | 一种博舒替尼中间体的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| CA2500368A1 (en) * | 2002-10-04 | 2004-04-22 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
-
2004
- 2004-02-18 TW TW093103901A patent/TW200423938A/zh unknown
- 2004-02-18 US US10/780,973 patent/US20040229880A1/en not_active Abandoned
- 2004-02-19 AU AU2004216235A patent/AU2004216235A1/en not_active Withdrawn
- 2004-02-19 RU RU2005129333/04A patent/RU2005129333A/ru not_active Application Discontinuation
- 2004-02-19 KR KR1020057015377A patent/KR20050102133A/ko not_active Withdrawn
- 2004-02-19 MX MXPA05008706A patent/MXPA05008706A/es unknown
- 2004-02-19 CA CA002516418A patent/CA2516418A1/en not_active Abandoned
- 2004-02-19 WO PCT/US2004/004904 patent/WO2004075898A1/en not_active Ceased
- 2004-02-19 BR BR0407441-6A patent/BRPI0407441A/pt not_active IP Right Cessation
- 2004-02-19 EP EP04712889A patent/EP1594502A1/en not_active Withdrawn
- 2004-02-19 UA UAA200508924A patent/UA80472C2/uk unknown
- 2004-02-19 JP JP2006503706A patent/JP2006522023A/ja not_active Withdrawn
- 2004-02-19 CN CNA2004800046743A patent/CN1750824A/zh active Pending
- 2004-02-20 AR ARP040100546A patent/AR043253A1/es not_active Application Discontinuation
-
2005
- 2005-08-03 CR CR7931A patent/CR7931A/es not_active Application Discontinuation
- 2005-08-17 CO CO05081472A patent/CO5640114A2/es not_active Application Discontinuation
- 2005-08-18 ZA ZA200506621A patent/ZA200506621B/en unknown
- 2005-08-19 EC EC2005005972A patent/ECSP055972A/es unknown
- 2005-09-01 NO NO20054070A patent/NO20054070L/no not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120749B2 (en) | 2010-07-30 | 2015-09-01 | Oncotherapy Science, Inc. | Quinoline derivatives and MELK inhibitors containing the same |
| RU2582610C2 (ru) * | 2010-07-30 | 2016-04-27 | Онкотерапи Сайенс, Инк. | Производные хинолина и содержащие их ингибиторы melk |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200506621B (en) | 2008-02-27 |
| JP2006522023A (ja) | 2006-09-28 |
| ECSP055972A (es) | 2006-01-16 |
| NO20054070L (no) | 2005-11-14 |
| CA2516418A1 (en) | 2004-09-10 |
| AU2004216235A1 (en) | 2004-09-10 |
| KR20050102133A (ko) | 2005-10-25 |
| AR043253A1 (es) | 2005-07-20 |
| EP1594502A1 (en) | 2005-11-16 |
| BRPI0407441A (pt) | 2006-01-31 |
| WO2004075898A1 (en) | 2004-09-10 |
| TW200423938A (en) | 2004-11-16 |
| US20040229880A1 (en) | 2004-11-18 |
| CO5640114A2 (es) | 2006-05-31 |
| NO20054070D0 (no) | 2005-09-01 |
| CR7931A (es) | 2006-02-07 |
| CN1750824A (zh) | 2006-03-22 |
| MXPA05008706A (es) | 2005-10-05 |
| UA80472C2 (en) | 2007-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005129333A (ru) | 4-[(2,4-дихлор-5-метоксифенил)амино]-6-алкокси-3-хинолинкарбонитрилы для лечения ишемического повреждения | |
| AU2009210655B2 (en) | Treatment of bladder diseases with a TLR7 activator | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| KR102372194B1 (ko) | Lsd1 억제제를 이용한 다발성 경화증의 치료방법 | |
| JP2000001434A (ja) | コルチコトロピン放出因子アンタゴニストを含む医薬組成物 | |
| KR20150020301A (ko) | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 | |
| JP2002527392A (ja) | 末梢的に作用する抗掻痒アヘン剤 | |
| JP2006522023A5 (https=) | ||
| JP2009525265A5 (https=) | ||
| JP5148478B2 (ja) | マラリア治療用のフェロキンとアーテミシニン誘導体との組合せ | |
| US6897229B2 (en) | Synergistic combination comprising roflumilast and a PDE-3 inhibitor | |
| JP2003522768A5 (https=) | ||
| WO2008124823A1 (en) | Method of treating melanoma | |
| JP2008521934A5 (https=) | ||
| RU2003136068A (ru) | Формы гатифлоксацина для применения в педиатрии | |
| JP5469095B2 (ja) | 急性マラリアを治療するためのビス−チアゾリウム塩またはこれらの前駆体およびアルテミシニンまたはこれらの誘導体の組み合わせ | |
| US20090163544A1 (en) | Use of NK-3 Receptor Antagonists for the Treatment of Nausea and Vomiting | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| JP2010536827A (ja) | ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体 | |
| JP2004509870A5 (https=) | ||
| JP2004509869A5 (https=) | ||
| RU2003108860A (ru) | Тиенопиримидины | |
| JP2001505218A (ja) | 認識作用強化薬の製造における２−（４−メトキシフェニル）−ピラゾロ（４，３−ｃ）キノリン−３−オンの使用 | |
| RU2003131963A (ru) | Производные 4-(фенил-(пиперидин-4-ил)-амино)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств | |
| US20230015906A1 (en) | Drug combination containing tlr7 agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090312 |